The stock of Geron Corporation (NASDAQ:GERN) is a huge mover today! About 1.28 million shares traded hands. Geron Corporation (NASDAQ:GERN) has declined 15.71% since March 9, 2016 and is downtrending. It has underperformed by 23.13% the S&P500.
The move comes after 9 months negative chart setup for the $348.81 million company. It was reported on Oct, 12 by Barchart.com. We have $1.92 PT which if reached, will make NASDAQ:GERN worth $48.83M less.
Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on November, 3. They expect $-0.06 earnings per share, down 135.29% or $0.23 from last year’s $0.17 per share. After $-0.05 actual earnings per share reported by Geron Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
Geron Corporation (NASDAQ:GERN) Ratings Coverage
Out of 2 analysts covering Geron (NASDAQ:GERN), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Geron has been the topic of 4 analyst reports since August 8, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by Piper Jaffray given on Monday, December 7. Zacks downgraded the shares of GERN in a report on Saturday, August 8 to “Hold” rating. The company was maintained on Tuesday, September 13 by FBR Capital. The stock of Geron Corporation (NASDAQ:GERN) earned “Buy” rating by MLV on Monday, August 10.
According to Zacks Investment Research, “Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.”
Insitutional Activity: The institutional sentiment decreased to 0.6 in 2016 Q2. Its down 0.79, from 1.39 in 2016Q1. The ratio fall, as 16 funds sold all Geron Corporation shares owned while 44 reduced positions. 8 funds bought stakes while 28 increased positions. They now own 61.08 million shares or 8.99% less from 67.11 million shares in 2016Q1.
The New York-based New York State Common Retirement Fund has invested 0% in Geron Corporation (NASDAQ:GERN). Amer Grp Inc accumulated 86,915 shares or 0% of the stock. The Texas-based Teacher Retirement Sys Of Texas has invested 0% in Geron Corporation (NASDAQ:GERN). Janney Montgomery Scott Limited Liability Company has 77,200 shares for 0% of their US portfolio. Kcg has 0.01% invested in the company for 92,737 shares. California State Teachers Retirement has 0% invested in the company for 316,594 shares. Deutsche State Bank Ag last reported 0% of its portfolio in the stock. Moreover, Bnp Paribas Arbitrage has 0% invested in Geron Corporation (NASDAQ:GERN) for 5,872 shares. The North Carolina-based Bank & Trust Of America De has invested 0% in Geron Corporation (NASDAQ:GERN). Morgan Stanley holds 0% of its portfolio in Geron Corporation (NASDAQ:GERN) for 57,654 shares. Nuveen Asset Ltd Company has invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Dafna Management Lc last reported 285,000 shares in the company. Fifth Third Bank & Trust has 0% invested in the company for 16,000 shares. Ameritas Inv Partners holds 13,372 shares or 0% of its portfolio. Fernwood Invest Ltd Company reported 16,000 shares or 0.04% of all its holdings.
More important recent Geron Corporation (NASDAQ:GERN) news were published by: Fool.com which released: “Here’s Why Geron Corporation Tumbled 16% in September” on October 07, 2016, also Streetinsider.com published article titled: “Geron Corp (GERN), Janssen Pharma Enter Exclusive Licensing Agreement”, Seekingalpha.com published: “Geron: Promising Signs” on October 03, 2016. More interesting news about Geron Corporation (NASDAQ:GERN) was released by: Seekingalpha.com and their article: “Geron: Uncertainties Abound In Imetelstat Clinical Trial” with publication date: September 15, 2016.
GERN Company Profile
Geron Corporation (Geron), incorporated on November 28, 1990, is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Firm operates through the segment, which includes discovery and development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that focuses and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.